Prognostic role of tumor microenvironment and immune- and autophagy-related genes in colorectal adenocarcinoma
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.This study identifies immune- and autophagy-related genes (IARGs) that can distinguish colorectal cancer from normal tissues. These IARGs show potential for improving clinical predictions of colorectal adenocarcinoma (COADREAD) risk.
Area Of Science
- Oncology
- Immunology
- Molecular Biology
Background
- Colorectal adenocarcinoma (COADREAD) is a leading cause of cancer mortality.
- Immunity and autophagy are implicated in COADREAD development, but their precise roles require further elucidation.
Purpose Of The Study
- To explore immune- and autophagy-related genes (IARGs) for prognostic risk assessment in COADREAD.
- To develop clinical prediction models for COADREAD based on IARGs.
- To understand the molecular underpinnings of COADREAD through IARG analysis.
Main Methods
- Integrated transcriptomic and clinical data from TCGA and GEO databases for 460 COADREAD cases.
- Identified 22 immune-autophagy-related genes (IARGs) by combining immune-related genes (IRGs) and autophagy-related genes (ARGs).
- Developed a prognostic risk model using LASSO and Cox regression, validated in external cohorts, and assessed immune infiltration using ssGSEA.
Main Results
- IARG data effectively distinguished between COADREAD and normal specimens.
- Specific genes like VEGFA, BIRC5, and BID were highly expressed in COADREAD, while TNFSF10 was lowly expressed.
- A low-risk group exhibited upregulated T cell and B cell receptor pathways and higher immune cell infiltration.
Conclusions
- Bioinformatic analysis confirmed IARGs can differentiate COADREAD from normal tissues.
- Immunity and autophagy are linked to a lower risk profile in COADREAD.
- Identified IARGs hold promise for enhancing clinical predictions of COADREAD risk.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...